Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Summit Therapeutics (SMMT 5.82%) stock got a real shot in the arm Friday with the initiation of coverage by a veteran financial services company. On news that Jefferies is now tracking the stock, investors snapped it up to push its price nearly 6% higher across the day's trading session.
Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Summit Therapeutics reached a milestone in its Phase III trial for ivonescimab, aiming to treat second-line EGFR mutated advanced NSCLC. The FDA has fast tracked the HARMONi trial. Positive Phase III results for ivonescimab versus KEYTRUDA in first-line NSCLC are promising, but registration in the US will require completion of HARMONI-7, which has just begun recruiting. Top-line data from the HARMONi trial is expected in mid-2025, potentially leading to FDA approval with complete enrollment as of Q3.
Warning: This Skyrocketing Stock Has a Hidden Risk
Up 860% in the last 12 months alone, Summit Therapeutics (SMMT -2.53%) is a skyrocketing stock that likely has more upside in store.
Why Summit Therapeutics Stock Was a Winner Today
A cancer drug has vast potential for the company, says a pundit newly following it.
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiated coverage on Summit Therapeutics Inc. SMMT, noting the company's initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed ivonescimab (PD-1 X VEGF bispecific) from Akeso for $500 million upfront and $5 billion in potential milestones.
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Summit Therapeutics Inc. NASDAQ: SMMT is a development-stage biotech company specializing in novel therapies for oncology and infectious diseases. Their leading drug candidate is Ivonescimab, an immunotherapy treatment being tested on non-small cell lung cancer (NSCLC).
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.
Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and CEO Maky Zanganeh - CEO and President Manmeet Soni - COO and CFO Allen Yang - Chief Medical Officer Conference Call Participants Mitchell Kapoor - H. C. Wainwright Brad Canino - Stifel Yigal Nochomovitz - Citi Operator Good morning.
Is Summit Therapeutics a Millionaire Maker?
The potential upside of this stock is undeniably meaty.
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?
Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy.
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.
